

PLATINUM INT'L HEALTH CARE FUND ARSN 107 023 530

31 March 2013

FACTS

Portfolio Value \$54.53 mn Fund commenced 10 November 2003 A\$20,000 or NZ\$25,000 Minimum investment Regular Investment Plan (min.) A\$200 or NZ\$250 per mth/qtr Income distribution date Annual, 30 June

Sydney Business Day Unit valuation

App 1.3194 Unit prices Red 1.3128

FEES

Entry fee Nil Exit fee Nil

Management Expense Ratio/ 1.54% per annum Indirect Cost Ratio (MER/ICR) (inclusive of investment & administration costs)

Brokerage paid Nil

Buy/sell spread 0.5% total

PERFORMANCE ¹		
	FUND %	MSCI %
1 month	0.25	3.55
3 months	10.18	13.50
6 months	12.21	14.61
1 year	23.30	23.89
2 years (compound pa)	16.06	17.79
3 years (compound pa)	11.48	9.11
5 years (compound pa)	8.95	6.29
7 years (compound pa)	3.40	1.05
Since inception (compound pa)	5.55	3.87

!			
INVESTED POSITION	ON ³		
	LONG %	NET %	CURRENCY %
Australia	1.3	1.3	9.0
Belgium	3.0	3.0	
Brazil	1.4	1.4	1.4
Denmark	4.0	4.0	4.0
France	5.9	5.9	
Germany	6.1	6.1	
Italy	3.5	3.5	
Japan	3.8	3.8	4.6
Sweden	4.2	4.2	4.2
Switzerland	9.0	9.0	6.2
UK	5.2	5.2	5.2
US	27.9	26.3	34.8
Total	75.3	73.7	
Canadaian\$			2.2
Euro			19.0
HK\$			2.3
Korean Won			1.8
Norwegian Krone			1.4
Singapore\$			3.9
Cash & Accruals	24.7	26.3	
Total	100.0	100.0	100.0
Long - 46 stocks Short	- 1 index		

1. Investment returns are calculated using the Fund's unit price and represent the combined income and capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The

investment returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns can be negative (particularly in the short-term).

be riegative (particularly in the short-term).

2. The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund since inception relative to the MSCI All Country World Health Care Net Index in A\$.

The investment returns are calculated using the Fund's unit price.

They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's individual chark solutions are account heldings will have received by the the

Platinum's individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only.

3. The "Long %" represents the exposure of physical holdings and long stock derivatives. The "Net %" represents the exposure of physical holdings and both long and short derivatives.

The "Currency %" represents the currency exposure for the Fund's Portfolio, taking into

account currency hedging.

4. Top Ten positions shows the Fund's top long share exposure positions. Long derivative exposures are included, however, short derivative exposures are not.

PERFORMANC	E GRA	<u>PH</u> 2			
\$36,000 -]	Platinum	Int'l Heal	lth Care F	und
\$33,000				66.	3%
\$30,000 -					7.
\$27,000 -		AN	h		
\$24,000 -	A		M !	N	70,00
\$21,000 -	W		MECLA	W.	ealth Care
\$18,000 -		V	MISCIA	. world H	42.9%
\$15,000 -		1	-	1	
20	003	2005	2007	2009	2011

Source: Factset and Platinum

TOP TEN POSITIONS ⁴			
<u>STOCK</u>	<u>COUNTRY</u>	<u>INDUSTRY</u>	<u>%</u>
Sanofi SA	France	Pharmaceuticals	3.5
Teva Pharmaceuticals Ind	United States	Pharmaceuticals	2.7
Qiagen NV	Germany	Health Equip & Servs	2.7
Novartis AG	Switzerland	Pharmaceuticals	2.6
Sartorius AG	Germany	Health Equip & Servs	2.6
Pfizer Inc	United States	Pharmaceuticals	2.4
Gilead Sciences Inc	United States	Biotechnology	2.4
Ipsen SA	France	Pharmaceuticals	2.4
Alere Inc	United States	Health Equip & Servs	2.1
Immunogen Inc	United States	Biotechnology	2.1

INDUSTRY BREAKDOWN ³ SECTOR Pharmaceuticals Health Equipment & Services Biotechnology Healthcare Providers Misc Manufacturing Chemicals		
<u>SECTOR</u>	LONG %	<u>NET %</u>
Pharmaceuticals	40.5	40.5
Health Equipment & Services	13.4	13.4
Biotechnology	11.4	11.4
Healthcare Providers	3.8	3.8
Misc Manufacturing	3.0	3.0
Chemicals	1.6	1.6
Electrical Equipment	1.6	1.6
Electrical Equipment Equity Funds* *Includes index short position		(1.6)
*Includes index short position		

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management (Platinum) is the responsible entity and issuer of units in the Platinum Int'l Health Care Fund (the Fund). The Platinum Trust Product Disclosure Statement No.8 and Supplementary PDS (together PDS) provides details about the Fund. You can obtain a copy of the PDS from Platinum's website, www.platinum.com.au, or by contacting Investor Services on 1300 726 700 (Australian investors only), 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via Invest@platinum.com.au

Invest@platinum.com.au. Before making any investment decision you need to consider (with your financial adviser) your particular investment needs, objectives and financial circumstances. You should refer to the PDS when deciding to acquire, or continue to hold, units in the Fund. DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Platinum does not guarantee the repayment of capital, payment of income or the Fund's performance. Platinum is a member of the Platinum Group of companies.